Immunovia AB (publ) (“Immunovia”) today announced the registration details for the company’s Virtual Investor Day on Tuesday, June 30, 2020 , from 2:00 to 4:00 pm CET . The online event will feature presentations by Immunovia’s Chairman, Carl Borrebaeck ; CEO, Mats Grahn ; Chief Commercial Officer, Laura Chirica ; Senior VP
| LUND, SWEDEN, June 26, 2020 /PRNewswire/ -- Immunovia (publ) (“Immunovia”) today announced the registration details for the company’s Virtual Investor Day on Tuesday, June 30, 2020, from 2:00 to 4:00 pm CET. The online event will feature presentations by Immunovia’s Chairman, Carl Borrebaeck; CEO, Mats Grahn; Chief Commercial Officer, Laura Chirica; Senior VP Sales North America, Michael Pettigrew; and Dr Thomas King, Medical Director. Please register for Immunovia’s Virtual Investor Day on June 30, 2020 2:00 PM CET at: https://attendee.gotowebinar.com/register/9213689045753501711 After registering, you will receive a confirmation email containing information about joining the webinar. About Immunovia
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”.
The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden. The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world’s largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently entering the final validation for sales start Q4 2020. When validated, IMMray™ PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome. Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and Lund, Sweden will provide laboratory testing services in two accredited reference laboratories. Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com. For more information, please contact: This information was brought to you by Cision http://news.cision.com The following files are available for download:
SOURCE Immunovia AB | ||
Company Codes: Berlin:0G8X, Bloomberg:IMMNOV@SS, ISIN:SE0006091997, OTC-PINK:IMMVF, RICS:IMMNOV.ST, Stockholm:IMMNOV, LSE:0G8X |
View original content:
